Cyclooxygenase and prostaglandin synthases: Roles in plaque stability and instability in humans

Current Opinion in Lipidology

Volumn 20, Issue 5, 2009, Pages 402-408

  Santovito, Donato ^a   Mezzetti, Andrea ^a   Cipollone, Francesco ^a  

^a Italian Society for the Study of Atherosclerosis   (Italy)

Author keywords

Atherosclerosis; Cyclooxygenase; Metalloproteinases; Plaque stability

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; PROSTAGLANDIN SYNTHASE;

ACUTE CORONARY SYNDROME; ARACHIDONIC ACID METABOLISM; ATHEROSCLEROTIC PLAQUE; CEREBROVASCULAR ACCIDENT; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; ICOSANOID METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ATHEROSCLEROSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MICROSOMES;

EID: 73349083062     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832fa22c     Document Type: Review

References (45)

1. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41:15S-22S.
2. Loftus IM, Naylor R, Goodall S, et al. Increased matrix- metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 2000; 31:40-47.
3. Cipollone F, Prontera C, Pini B, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001; 104:921-927.
4. Kuge Y, Takai N, Ishino S, et al. Distribution profiles of membrane type-1 matrix metalloproteinase (MT1-MMP), matrix metalloproteinase-2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: comparison with plaque instability analysis. Biol Pharm Bull 2007; 30:1634-1640.
5. Corcoran ML, Stetler-Stevenson WG, DeWitt DL, Wahl LM. Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases production by human monocytes. Arch Biochem Biophys 1994; 310:481-488. (Pubitemid 24172696)
6. Chandrasekharan NV, Dai H, Roos KLT. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99:13926-13931. (Pubitemid 35215482)
7. Matsumoto H, Naraba H, Murakami M, et al. Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide- stimulated rat peritoneal macrophages. Biochem Biophys Res Commun 1997; 230:110-114.
8. Kang KB, Van Der Zypp A, lannazzo L, Majewski H. Age-related changes in monocyte and platelet cyclooxygenase expression in healthy male humans and rats. Transi Res 2006; 148:289-294.
9. Herron GS, Werb Z, Dwyer K et al. Secretion of metalloproteinases. In: Holmes DR, Wester W, Thompson RW, Reilly JM, editors. Prostaglandin E2 synthesis, and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997; 25:810-815.
10. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation In LDL receptor-deficient mice. Circulation 2002; 105:1816-1823.
11. Cipollone F, lezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemie control. Circulation 2003; 108:1070-1077.
12. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105:1605-1612. (Pubitemid 30390311)
13. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 2000; 35:68-75. (Pubitemid 30054239)
14. Brilla CG, Zhou G, Rupp H, et al. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 1995; 76:8D-13D.
15. Cipollone F, Fazia M, lezzi A, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109:1482-1488.
16. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101:1586-1593.
17. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-444. (Pubitemid 32147251)
18. Choi BG, Vilahur G, Zafar MU, et al. Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis 2008; 201:76-84.
19. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287:847-857. (Pubitemid 34252031)
20. Takayama K, Garciá-Cardeña G, Sukhova GK, et al. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002; 277:44147-44154.
21. McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 2002; 110:651 658.
22. Miyaura C, Inada M, Suzawa T, et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000; 275:19819-19823.
23. Cipollone F, Fazia F, lezzi A, et al. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol 2005; 25:1925-1931.
24. Faour WH, He Y, He QW, et al. Prostaglandin E2 regulates the level and stability of cyclooxygenase-2 m RNA through activation of p38 mitogenactivated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 2001; 276:31720-31731. (Pubitemid 37384819)
25. Babaev VR, Chew JD, Ding L, et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab 2008; 8:492-501.
26. Papafili A, Hill MR, Brull DJ, et al. A common promoter variant in cyclooxygenase-2 represses gene expression: evidence for a role in the acute phase inflammatory response. Arterioscler Thromb Vase Biol 2002; 22:1631-1636.
27. Cipollone F, Patrono C. Cyclooxygenase-2 polymorphism. Putting a brake on the inflammatory response to vascular injury? Arterioscler Thromb Vase Biol 2002; 22:1516-1518.
28. Furukado S, Sakaguchl M, Yamagami H, et al. Cyolo-oxygenase-2-765G > C promoter variants are associated with lower carotid plaque echogenicity in Japanese. Cerebrovasc Dis 2009; 27:91-98.
29. Cipollone F, Toniato E, Martinotti S, et al., Identification of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an Inherited protective factor against myocardial Infarction and stroke. JAMA 2004; 291:2221-2228.
30. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide sinthase are selectively upregulated by steady laminar shear stress. Proc Natl Acad Sci U S A 1996;93:10417-10422. (Pubitemid 26314637)
31. Rudock ME, Liu Y, Zlegler JT, et al. Association of polymorphisms in cyclooxygenase (COXJ-2 with coronary and calcium in the Diabetes Heart Study. Atherosclerosis 2009; 203:459-465.
32. Bombardier C, Laine L, Relcin A, et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000; 343:1520-1528.
33. Bresaller RS, Sandler RS, Quan H, et al., for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemopreventlon trial. N Engl J Med 2005; 352:1092-1102.
34. Bertagnolll MM, Eagle CJ, Zauber AG, et al., APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873-884.
35. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-Inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study - a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
36. Arber N, Eagle CJ, Spicak J, et al., PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885-895.
37. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-1091.
38. White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific Inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther2004; 11xt:244-250.
39. Farkouh ME, Kirshner H, Harrington RA, et al., TARGET Study Group. Comparison of lumlracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364:675-684.
40. Cannon CP, Curtis SP, FitzGerald GA, et al., MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368:1771-1781.
41. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308.
42. Flavahan NA. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci. 2007; 28:106-110. (Pubitemid 46283588)
43. Catella-Lawson F, Mardini IA, Kapoor S, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective Inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96:272-277.
44. Buerkle MA, Lehrer S, Sohn HY, et al. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 2004; 110:2053-2059. (Pubitemid 39331921)
45. Pidgeon GP, Tamosluniene R, Chen G, et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 2004; 110:2701-2707.